dibotatug
AssetAlso called DR-01
Targets CD94 to deplete cytotoxic T cells and natural killer cells through antibody-dependent cellular cytotoxicity.
- Stage
- Phase 1
- Modality
- Antibody
- Target
- KLRD1
- 6
- Indications
- 1
- Trial
- 1
- Developer
Indications
6Aplastic anemias
Phase 1, Recruiting, NCT07712562, clinicaltrials.gov, Nov 5, 2026
Bone marrow failure syndrome
Phase 1, Recruiting, NCT07712562, clinicaltrials.gov, Nov 5, 2026
Non severe aplastic anemia
Phase 1, Recruiting, NCT07712562, clinicaltrials.gov, Nov 5, 2026
3 more
In the full profile
- Target and mechanism1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.